Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TransThera Sciences (Nanjing)FRA:J8J +2.91%20 PB Ratio is 8.35 as of Aug. 21, 2026, which is 74% below its 10-year median of 31.79. GuruFocus rates FRA:J8J with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 1,213 Biotechnology companies, TransThera Sciences (Nanjing) ranks worse than 84.09% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
TransThera Sciences (Nanjing) PB Ratio Related Terms
TransThera Sciences (Nanjing) PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TransThera Sciences (Nanjing) PB Ratio Chart
TransThera Sciences (Nanjing) Annual Data
Trend
Dec23
Dec24
Dec25
PB Ratio
0.00
0.00
0.00
TransThera Sciences (Nanjing) Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
PB Ratio
0.00
0.00
0.00
0.00
0.00
FRA:J8J vs VRTX, REGN, RVMD: PB Ratio Comparison
For the Biotechnology subindustry, TransThera Sciences (Nanjing)'s PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TransThera Sciences (Nanjing) PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TransThera Sciences (Nanjing)'s PB Ratio distribution charts can be found below:
* The bar in red indicates where TransThera Sciences (Nanjing)'s PB Ratio falls into.
TransThera Sciences (Nanjing) PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
TransThera Sciences (Nanjing) (FRA:J8J) has a PB Ratio of 8.35 as of Aug. 21, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on TransThera Sciences (Nanjing) and its competitors. This is 74% below median its historical median of 31.79. Over the past decade, TransThera Sciences (Nanjing)'s PB Ratio has ranged from 4.22 to 102.41. According to the industry distribution chart, TransThera Sciences (Nanjing) ranks #1020 out of 1213 companies in the Biotechnology industry, placing it in the top 84.1%.
Is TransThera Sciences (Nanjing)'s PB Ratio too high?
TransThera Sciences (Nanjing)'s current PB Ratio of 8.35 is 74% below median its 10-year median of 31.79. Over the past 10 years, this metric has ranged from a low of 4.22 to a high of 102.41. The Biotechnology industry median PB Ratio is 2.93. TransThera Sciences (Nanjing)'s value of 8.35 is 185% above this industry median. Based on the distribution chart, TransThera Sciences (Nanjing) ranks #1020 out of 1213 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TransThera Sciences (Nanjing) has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does TransThera Sciences (Nanjing)'s PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TransThera Sciences (Nanjing) ranks #1020 out of 1213 companies for PB Ratio. This places TransThera Sciences (Nanjing) in the lower half of its industry. The industry median PB Ratio is 2.93. TransThera Sciences (Nanjing)'s value of 8.35 is 185% above this benchmark. Historically, TransThera Sciences (Nanjing)'s own PB Ratio has ranged from 4.22 to 102.41 over the past decade. While the company's 10-year median is 31.79 vs. the industry median of 2.93, TransThera Sciences (Nanjing) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,213 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TransThera Sciences (Nanjing)'s current PB Ratio of 8.35 is 185% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on TransThera Sciences (Nanjing) and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TransThera Sciences (Nanjing)'s current PB Ratio is 8.35, which is 74% below median its own 10-year median of 31.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransThera Sciences (Nanjing) stock overvalued right now?
TransThera Sciences (Nanjing) (FRA:J8J) has a current PB Ratio of 8.35. The current PB Ratio is 8.35, which is 74% below median its 10-year median of 31.79 and 185% above the Biotechnology industry median of 2.93. TransThera Sciences (Nanjing)'s overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For TransThera Sciences (Nanjing) (FRA:J8J), the current PB Ratio is 8.35 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TransThera Sciences (Nanjing) Inc is a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing inventive small molecule therapies for oncology, inflammatory and cardiometabolic diseases. It has internally discovered and developed one Core Product Tinengotinib (TT-00420) and built a pipeline of five clinical stage product candidates and one preclinical stage product candidate with its fully-integrated in-house R&D system. Its core Product Tinengotinib is a multi-targeted kinase (MTK) inhibitor targeting three key pathways. It is undergoing two pivotal/registrational clinical trials for the treatment of cholangiocarcinoma that has progressed following prior FGFR inhibitor therapy, one being conducted in China.
20GF Score
Get the complete analysis for FRA:J8J
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:J8J has been successfully added to your 
